CommSec's Tom Piotrowski speaks with Avita Medical (AVH) CEO, Dr Mike Perry about:
- Mike Perry’s recent appointment as CEO of AVH and the broader strategy that will guide the group over the medium term;
- The key benefits of AVH’s ReCell product including early wound closure with less donor skin, better functional and cosmetic outcomes for improved quality of life, reduced hospital stay and a reduced need for reconstructive procedures and scar management;
- The key milestones for AVH over the coming 18 months including the commercialisation of the ReCell product in the US;
- The ongoing progress of the relationship with the US Biomedical Advanced Research and Development Authority (BARDA).
To view more Executive Series interviews, visit:
Please sign in to comment on this wire.